Category: Blog

The National cancer plan 2026 sets out one of the most ambitious shifts in UK oncology policy in a generation. Its headline aim is clear: by 2035, three in four people diagnosed with cancer in England should be cancer-free or living well five years after diagnosis, compared with around 60% today. Achieving that target will…

World Cancer Day, observed each year on 4th February, is a global initiative focused on raising awareness of cancer and accelerating action across prevention, diagnosis, treatment and research. For organisations working in clinical research and drug development, the day is also an opportunity to reflect on the progress made, and the work still required to…

Good Laboratory Practice (GLP) is a set of criteria used to ensure quality assurance in non-clinical studies. GLP principles are concerned with the organisational processes by which studies are planned, performed, monitored, recorded, reported and archived. These guidelines support the integrity, reliability and traceability of safety data used for regulatory submissions.  GLP is commonly applied…

Welcome back to our blog series where we share some of the highlights and key takeaways from our fireside chat with CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger. Our last blog post covered what AI-enabled causal modelling is, how it is different from other models, and where you might want to…

Can early utilisation of AI de-risk and accelerate clinical development for drug developers? Recent announcements suggest large pharma companies are betting big on AI. AstraZeneca recently announced a $247 million deal with an AI vendor to support identifying new oncology drug candidates[1]. Sanofi has announced a collaboration with two separate AI vendors, worth up to…

Clinical trials are essential in advancing treatments for multiple sclerosis (MS). With no cure currently available, ongoing research is critical to uncovering new, more effective therapies. Simbec-Orion is a Clinical Research Organisation with nearly five decades of experience, specialising in oncology and rare diseases. This article explores the vital role that clinical trials play in…

Pneumonia is an infection of the respiratory system, resulting in inflammation of the alveoli, or air sacs, within your lungs. This causes symptoms like coughing, breathing problems, fatigue, a fever and more. Here at Simbec-Orion, we bring five decades of clinical research expertise, focused on rare diseases and oncology. What is Pneumonia? As a respiratory illness,…

Interstitial Lung Disease, otherwise known as ILD, is a grouping of rare lung conditions that currently have no known cure. With this in mind, clinical trials play a pivotal role in advancing knowledge and discovering more effective treatments.At Simbec-Orion, we bring nearly 50 years of experience as a Clinical Research Organisation focused on oncology and…

Phase I and Phase II clinical trials are the first stage of testing a new medical treatment, drug, or device in human subjects. The purpose of these early-stage trials is primarily to assess the safety, tolerability, and potential side effects of a new treatment. You may also be interested in exploring early-phase oncology trials or…